메뉴 건너뛰기




Volumn 13, Issue 12, 2012, Pages 1807-1816

Retigabine/Ezogabine, a KCNQ/KV7 channel opener: Pharmacological and clinical data

Author keywords

Antiepileptic drug; Epilepsy; Pharmacotherapy; Potassium channel; Retigabine ezogabine

Indexed keywords

CARBAMAZEPINE; CARBAMIC ACID; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; DRUG METABOLITE; FLUPIRTINE; LAMOTRIGINE; PLACEBO; POTASSIUM CHANNEL KCNQ; RETIGABINE; VALPROIC ACID;

EID: 84864034772     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2012.706278     Document Type: Review
Times cited : (35)

References (58)
  • 1
    • 0037398465 scopus 로고    scopus 로고
    • The epidemiology of epilepsy revisited
    • Sander JW. The epidemiology of epilepsy revisited. Curr Opin Neurol 2003;16:165-170
    • (2003) Curr. Opin. Neurol. , vol.16 , pp. 165-170
    • Sander, J.W.1
  • 2
    • 0034702511 scopus 로고    scopus 로고
    • Management of epilepsy in adolescents and adults
    • Brodie MJ, French JA. Management of epilepsy in adolescents and adults. Lancet 2000;356:323-329
    • (2000) Lancet , vol.356 , pp. 323-329
    • Brodie, M.J.1    French, J.A.2
  • 3
    • 72049122652 scopus 로고    scopus 로고
    • Definition of refractory epilepsy: Defining the indefinable
    • Kwan P, Brodie MJ. Definition of refractory epilepsy: Defining the indefinable? Lancet Neurol 2010;9:27-29
    • (2010) Lancet Neurol. , vol.9 , pp. 27-29
    • Kwan, P.1    Brodie, M.J.2
  • 4
    • 0032483972 scopus 로고    scopus 로고
    • KCNQ2 and KCNQ3 potassium channel subunits: Molecular correlates of the M-channel
    • Wang HS, Pan Z, Shi W, et al. KCNQ2 and KCNQ3 potassium channel subunits: Molecular correlates of the M-channel. Science 1998;282:1890-1893
    • (1998) Science , vol.282 , pp. 1890-1893
    • Wang, H.S.1    Pan, Z.2    Shi, W.3
  • 5
    • 27644518764 scopus 로고    scopus 로고
    • Pathways modulating neural kcnq/m KV7 potassium channels
    • Delmas P, Brown DA. Pathways modulating neural kcnq/m KV7 potassium channels. Nat Rev Neurosci 2005;6:850-862
    • (2005) Nat. Rev. Neurosci. , vol.6 , pp. 850-862
    • Delmas, P.1    Brown, D.A.2
  • 7
    • 0029088690 scopus 로고
    • Reduction of spike frequency adaptation and blockade of M-current in rat CA1 pyramidal neurones by linopirdine (DuP 996), a neurotransmitter release enhancer
    • Aiken SP, Lampe BJ, Murphy PA, et al. Reduction of spike frequency adaptation and blockade of M-current in rat CA1 pyramidal neurones by linopirdine (DuP 996), a neurotransmitter release enhancer. Br J Pharmacol 1995;115:1163-1168
    • (1995) Br. J. Pharmacol. , vol.115 , pp. 1163-1168
    • Aiken, S.P.1    Lampe, B.J.2    Murphy, P.A.3
  • 8
    • 0027456560 scopus 로고
    • Flupirtine a review of its pharmacological properties, and therapeutic efficacy in pain states
    • Friedel HA, Fitton A. Flupirtine. A review of its pharmacological properties, and therapeutic efficacy in pain states. Drugs 1993;45:548-569
    • (1993) Drugs , vol.45 , pp. 548-569
    • Friedel, H.A.1    Fitton, A.2
  • 9
    • 0029969951 scopus 로고    scopus 로고
    • D-23129: A new anticonvulsant with a broad spectrum activity in animal models of epileptic seizures
    • Rostock A, Tober C, Rundfeldt C, et al. D-23129: A new anticonvulsant with a broad spectrum activity in animal models of epileptic seizures. Epilepsy Res 1996;23:211-223
    • (1996) Epilepsy Res. , vol.23 , pp. 211-223
    • Rostock, A.1    Tober, C.2    Rundfeldt, C.3
  • 10
    • 0029891002 scopus 로고    scopus 로고
    • D-23129: A potent anticonvulsant in the amygdala kindling model of complex partial seizures
    • Tober C, Rostock A, Rundfeldt C, et al. D-23129: A potent anticonvulsant in the amygdala kindling model of complex partial seizures. Eur J Pharmacol 1996;303:163-169
    • (1996) Eur. J. Pharmacol. , vol.303 , pp. 163-169
    • Tober, C.1    Rostock, A.2    Rundfeldt, C.3
  • 11
    • 0033032546 scopus 로고    scopus 로고
    • Effects of retigabine (D-23129) on different patterns of epileptiform activity induced by 4-aminopyridine in rat entorhinal cortex hippocampal slices
    • Armand V, Rundfeldt C, Heinemann U. Effects of retigabine (D-23129) on different patterns of epileptiform activity induced by 4-aminopyridine in rat entorhinal cortex hippocampal slices. Naunyn Schmiedebergs Arch Pharmacol 1999;359:33-39
    • (1999) Naunyn Schmiedebergs Arch. Pharmacol. , vol.359 , pp. 33-39
    • Armand, V.1    Rundfeldt, C.2    Heinemann, U.3
  • 12
    • 0033989219 scopus 로고    scopus 로고
    • Effects of retigabine (D-23129) on different patterns of epileptiform activity induced by low magnesium in rat entorhinal cortex hippocampal slices
    • Armand V, Rundfeldt C, Heinemann U. Effects of retigabine (D-23129) on different patterns of epileptiform activity induced by low magnesium in rat entorhinal cortex hippocampal slices. Epilepsia 2000;41:28-33
    • (2000) Epilepsia , vol.41 , pp. 28-33
    • Armand, V.1    Rundfeldt, C.2    Heinemann, U.3
  • 13
    • 0033402130 scopus 로고    scopus 로고
    • The anticonvulsant retigabine potently suppresses epileptiform discharges in the low Ca2+ and low Mg2+ model in the hippocampal slice preparation
    • Dost R, Rundfeldt C. The anticonvulsant retigabine potently suppresses epileptiform discharges in the low Ca2+ and low Mg2+ model in the hippocampal slice preparation. Epilepsy Res 2000;38:53-66
    • (2000) Epilepsy Res. , vol.38 , pp. 53-66
    • Dost, R.1    Rundfeldt, C.2
  • 14
    • 18844476488 scopus 로고    scopus 로고
    • Effects of retigabine on rhythmic synchronous activity of human neocortical slices
    • Straub H, Kohling R, Hohling J, et al. Effects of retigabine on rhythmic synchronous activity of human neocortical slices. Epilepsy Res 2001;44:155-165
    • (2001) Epilepsy Res. , vol.44 , pp. 155-165
    • Straub, H.1    Kohling, R.2    Hohling, J.3
  • 15
    • 4544384631 scopus 로고    scopus 로고
    • Mice carrying the szt1 mutation exhibit increased seizure susceptibility and altered sensitivity to compounds acting at the m-channel
    • Otto JF, Yang Y, Frankel WN, et al. Mice carrying the szt1 mutation exhibit increased seizure susceptibility and altered sensitivity to compounds acting at the m-channel. Epilepsia 2004;45:1009-1016
    • (2004) Epilepsia , vol.45 , pp. 1009-1016
    • Otto, J.F.1    Yang, Y.2    Frankel, W.N.3
  • 16
    • 64949142097 scopus 로고    scopus 로고
    • Isobolographic characterization of interactions of retigabine with carbamazepine, lamotrigine, and valproate in the mouse maximal electroshock-induced seizure model
    • Luszczki JJ, Wu JZ, Raszewski G, Czuczwar SJ. Isobolographic characterization of interactions of retigabine with carbamazepine, lamotrigine, and valproate in the mouse maximal electroshock-induced seizure model. Naunyn Schmiedebergs Arch Pharmacol 2009;379:163-179
    • (2009) Naunyn Schmiedebergs Arch. Pharmacol. , vol.379 , pp. 163-179
    • Luszczki, J.J.1    Wu, J.Z.2    Raszewski, G.3    Czuczwar, S.J.4
  • 17
    • 21344462822 scopus 로고    scopus 로고
    • A potassium channel, the M-channel, as a therapeutic target
    • Surti TS, Jan LY. A potassium channel, the M-channel, as a therapeutic target. Curr Opin Investig Drugs 2005;6:704-711
    • (2005) Curr. Opin. Investig Drugs , vol.6 , pp. 704-711
    • Surti, T.S.1    Jan, L.Y.2
  • 18
    • 0037462422 scopus 로고    scopus 로고
    • The anticonvulsant retigabine attenuates nociceptive behaviours in rat models of persistent and neuropathic pain
    • Blackburn-Munro G, Jensen BS. The anticonvulsant retigabine attenuates nociceptive behaviours in rat models of persistent and neuropathic pain. Eur J Pharmacol 2003;460:109-116
    • (2003) Eur. J. Pharmacol. , vol.460 , pp. 109-116
    • Blackburn-Munro, G.1    Jensen, B.S.2
  • 19
    • 34547841517 scopus 로고    scopus 로고
    • The neuronal KCNQ channel opener retigabine inhibits locomotor activity and reduces forebrain excitatory responses to the psychostimulants cocaine, methylphenidate and phencyclidine
    • Hansen HH, Andreasen JT, Weikop P, et al. The neuronal KCNQ channel opener retigabine inhibits locomotor activity and reduces forebrain excitatory responses to the psychostimulants cocaine, methylphenidate and phencyclidine. Eur J Pharmacol 2007;570:77-88
    • (2007) Eur. J. Pharmacol. , vol.570 , pp. 77-88
    • Hansen, H.H.1    Andreasen, J.T.2    Weikop, P.3
  • 20
    • 52049097593 scopus 로고    scopus 로고
    • The mechanisms of neurodegenerative processes and current pharmacotherapy of Alzheimer's disease
    • Gongadze N, Antelava N, Kezeli T, et al. The mechanisms of neurodegenerative processes and current pharmacotherapy of Alzheimer's disease. Georgian Med News 2008;155:44-48
    • (2008) Georgian Med. News , vol.155 , pp. 44-48
    • Gongadze, N.1    Antelava, N.2    Kezeli, T.3
  • 21
    • 0033011118 scopus 로고    scopus 로고
    • Characterization of the K+ channel opening effect of the anticonvulsant retigabine in pc12 cells
    • Rundfeldt C. Characterization of the K+ channel opening effect of the anticonvulsant retigabine in pc12 cells. Epilepsy Res 1999;35:99-107
    • (1999) Epilepsy Res. , vol.35 , pp. 99-107
    • Rundfeldt, C.1
  • 22
    • 0034677733 scopus 로고    scopus 로고
    • The novel anticonvulsant retigabine activates M-currents in Chinese hamster ovary-cells tranfected with human KCNQ2/3 subunits
    • Rundfeldt C, Netzer R. The novel anticonvulsant retigabine activates M-currents in Chinese hamster ovary-cells tranfected with human KCNQ2/3 subunits. Neurosci Lett 2000B;282:73-76
    • (2000) Neurosci Lett. , vol.282 , pp. 73-76
    • Rundfeldt, C.1    Netzer, R.2
  • 23
    • 0033862433 scopus 로고    scopus 로고
    • Retigabine, a novel anti-convulsant, enhances activation of KCNQ2/Q3 potassium channels
    • Wickenden AD, Yu W, Zou A, et al. Retigabine, a novel anti-convulsant, enhances activation of KCNQ2/Q3 potassium channels. Mol Pharmacol 2000;58:591-600
    • (2000) Mol. Pharmacol. , vol.58 , pp. 591-600
    • Wickenden, A.D.1    Yu, W.2    Zou, A.3
  • 24
    • 0033916576 scopus 로고    scopus 로고
    • Modulation of KCNQ2/3 potassium channels by the novel anticonvulsant retigabine
    • Main MJ, Cryan JE, Dupere JR, et al. Modulation of KCNQ2/3 potassium channels by the novel anticonvulsant retigabine Mol Pharmacol 2000;58:253-262
    • (2000) Mol. Pharmacol. , vol.58 , pp. 253-262
    • Main, M.J.1    Cryan, J.E.2    Dupere, J.R.3
  • 25
    • 0035425653 scopus 로고    scopus 로고
    • Activation of expressed KCNQ potassium currents and native neuronal M-type potassium currents by the anti-convulsant drug retigabine
    • Tatulian L, Delmas P, Abogadie FC, et al. Activation of expressed KCNQ potassium currents and native neuronal M-type potassium currents by the anti-convulsant drug retigabine. J Neurosci 2001;21:5535-5545
    • (2001) J. Neurosci. , vol.21 , pp. 5535-5545
    • Tatulian, L.1    Delmas, P.2    Abogadie, F.C.3
  • 26
    • 27644518764 scopus 로고    scopus 로고
    • Pathways modulating neural kcnq/m (KV7) potassium channels
    • Delmas P, Brown DA. Pathways modulating neural kcnq/m (KV7) potassium channels. Nat Rev Neurosci 2005;6:850-862
    • (2005) Nat. Rev. Neurosci. , vol.6 , pp. 850-862
    • Delmas, P.1    Brown, D.A.2
  • 28
    • 0034303612 scopus 로고    scopus 로고
    • Neuronal KCNQ potassium channels: Physiology and role in disease
    • Jentsch TJ. Neuronal KCNQ potassium channels: Physiology and role in disease. Nat Rev Neurosci 2000;1:21-30
    • (2000) Nat. Rev. Neurosci. , vol.1 , pp. 21-30
    • Jentsch, T.J.1
  • 29
    • 15744400656 scopus 로고    scopus 로고
    • The new anticonvulsant retigabine favors voltage-dependent opening of the KV7.2 (KCNQ2) channel by binding to its activation gate
    • Wuttke TV, Seebohm G, Bail S, et al. The new anticonvulsant retigabine favors voltage-dependent opening of the KV7.2 (KCNQ2) channel by binding to its activation gate. Mol Pharmacol 2005;67:1009-1017
    • (2005) Mol. Pharmacol. , vol.67 , pp. 1009-1017
    • Wuttke, T.V.1    Seebohm, G.2    Bail, S.3
  • 30
    • 19044386394 scopus 로고    scopus 로고
    • Molecular determinants of KCNQ (KV7) K+ channel sensitivity to the anticonvulsant retigabine
    • Schenzer A, Friedrich T, Pusch M, et al. Molecular determinants of KCNQ (KV7) K+ channel sensitivity to the anticonvulsant retigabine. J Neurosci 2005;25:5051-5060
    • (2005) J. Neurosci. , vol.25 , pp. 5051-5060
    • Schenzer, A.1    Friedrich, T.2    Pusch, M.3
  • 31
    • 59449092002 scopus 로고    scopus 로고
    • Refinement of the binding site and mode of action of the anticonvulsant Retigabine on KCNQ K+ channels
    • Lange W, Geissendorfer J, Schenzer A, et al. Refinement of the binding site and mode of action of the anticonvulsant Retigabine on KCNQ K+ channels. Mol Pharmacol 2009;75:272-280
    • (2009) Mol. Pharmacol. , vol.75 , pp. 272-280
    • Lange, W.1    Geissendorfer, J.2    Schenzer, A.3
  • 32
    • 0036210933 scopus 로고    scopus 로고
    • Effects of the anticonvulsant retigabine on cultured cortical neurons: Changes in electroresponsive properties and synaptic transmission
    • Otto JF, Kimball MM, Wilcox KS. Effects of the anticonvulsant retigabine on cultured cortical neurons: Changes in electroresponsive properties and synaptic transmission. Mol Pharmacol 2002;61:921-927
    • (2002) Mol. Pharmacol. , vol.61 , pp. 921-927
    • Otto, J.F.1    Kimball, M.M.2    Wilcox, K.S.3
  • 33
    • 0034533728 scopus 로고    scopus 로고
    • Investigations into the mechanism of action of the new anticonvulsant retigabine interaction with GABAergic and glutamatergic neurotransmission and with voltage gated ion channels
    • Rundfeldt C, Netzer R. Investigations into the mechanism of action of the new anticonvulsant retigabine. Interaction with GABAergic and glutamatergic neurotransmission and with voltage gated ion channels. Arzneimittelforschung 2000A;50:1063-1070
    • (2000) Arzneimittelforschung , vol.50 , pp. 1063-1070
    • Rundfeldt, C.1    Netzer, R.2
  • 34
    • 0038293217 scopus 로고    scopus 로고
    • Pharmacokinetic interaction between retigabine and lamotrigine in healthy subjects
    • Hermann R, Knebel NG, Niebch G, et al. Pharmacokinetic interaction between retigabine and lamotrigine in healthy subjects. Eur J Clin Pharmacol 2003A;58:795-802
    • (2003) Eur. J. Clin. Pharmacol. , vol.58 , pp. 795-802
    • Hermann, R.1    Knebel, N.G.2    Niebch, G.3
  • 35
    • 0036152375 scopus 로고    scopus 로고
    • Multiple-dose, linear, dose-proportional pharmacokinetics of retigabine in healthy volunteers
    • Ferron GM, Paul J, Fruncillo R, et al. Multiple-dose, linear, dose-proportional pharmacokinetics of retigabine in healthy volunteers. J Clin Pharmacol 2002;42:175-182
    • (2002) J. Clin. Pharmacol. , vol.42 , pp. 175-182
    • Ferron, G.M.1    Paul, J.2    Fruncillo, R.3
  • 36
    • 0037261396 scopus 로고    scopus 로고
    • Effects of age and sex on the disposition of retigabine
    • Hermann R, Ferron GM, Erb K, et al. Effects of age and sex on the disposition of retigabine. Clin Pharmacol Ther 2003B;73:61-70
    • (2003) Clin. Pharmacol. Ther. , vol.73 , pp. 61-70
    • Hermann, R.1    Ferron, G.M.2    Erb, K.3
  • 37
    • 0037660846 scopus 로고    scopus 로고
    • Lack of pharmacokinetic interaction between retigabine and phenobarbitone at steady-state in healthy subjects
    • Ferron GM, Patat A, Parks V, et al. Lack of pharmacokinetic interaction between retigabine and phenobarbitone at steady-state in healthy subjects. Br J Clin Pharmacol 2003;56:39-45
    • (2003) Br. J. Clin. Pharmacol. , vol.56 , pp. 39-45
    • Ferron, G.M.1    Patat, A.2    Parks, V.3
  • 38
    • 80051777786 scopus 로고    scopus 로고
    • Retigabine
    • BIALER M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS
    • Hammond JMJ. Retigabine. In: BIALER M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS, Epilepsy Res 2010;92:113-116
    • (2010) Epilepsy Res. , vol.92 , pp. 113-116
    • Hammond, J.M.J.1
  • 39
    • 80051742205 scopus 로고    scopus 로고
    • Retigabine
    • BIALER M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS
    • Mansbach H. Retigabine. In: BIALER M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS, Epilepsy Res 2009;83:27-31
    • (2009) Epilepsy Res. , vol.83 , pp. 27-31
    • Mansbach, H.1
  • 40
    • 0038084973 scopus 로고    scopus 로고
    • Pharmacokinetic interaction between valproic acid, topiramate, phenytoin or carbamazepine and retigabine in epileptic patients
    • Ferron GM, Sachdeo R, Partiot A, et al. Pharmacokinetic interaction between valproic acid, topiramate, phenytoin or carbamazepine and retigabine in epileptic patients. Clin Pharmacol Ther 2001;69:P18
    • (2001) Clin. Pharmacol. Ther. , vol.69
    • Ferron, G.M.1    Sachdeo, R.2    Partiot, A.3
  • 41
    • 0030991641 scopus 로고    scopus 로고
    • In vitro glucuronidation of D-23129, a new anticonvulsant, by human liver microsomes and liver slices
    • McNeilly PJ, Torchin CD, Anderson LW, et al. In vitro glucuronidation of D-23129, a new anticonvulsant, by human liver microsomes and liver slices. Xenobiotica 1997;27:431-441
    • (1997) Xenobiotica , Issue.27 , pp. 431-441
    • McNeilly, P.J.1    Torchin, C.D.2    Anderson, L.W.3
  • 42
    • 0032930073 scopus 로고    scopus 로고
    • Metabolism of retigabine (D-23129), a novel anticonvulsant
    • Hempel R, Schupke H, McNeilly PJ, et al. Metabolism of retigabine (D-23129), a novel anticonvulsant. Drug Metab Dispos 1999;27:613-622
    • (1999) Drug Metab. Dispos. , vol.27 , pp. 613-622
    • Hempel, R.1    Schupke, H.2    McNeilly, P.J.3
  • 43
    • 0032906655 scopus 로고    scopus 로고
    • Retigabine N-glucuronidation and its potential role in enterohepatic circulation
    • Hiller A, Nguyen N, Strassburg CP, et al. Retigabine N-glucuronidation and its potential role in enterohepatic circulation. Drug Metab Dispos 1999;27:605-612
    • (1999) Drug Metab. Dispos , vol.27 , pp. 605-612
    • Hiller, A.1    Nguyen, N.2    Strassburg, C.P.3
  • 44
    • 33646497843 scopus 로고    scopus 로고
    • N-Glucuronidation of the antiepileptic drug retigabine: Results from studies with human volunteers, heterologously expressed human UGTs, human liver, kidney, and liver microsomal membranes of Crigler-Najjar type II
    • Borlak J, Gasparic A, Locher M, et al. N-Glucuronidation of the antiepileptic drug retigabine: Results from studies with human volunteers, heterologously expressed human UGTs, human liver, kidney, and liver microsomal membranes of Crigler-Najjar type II. Metabolism 2006;55:711-721
    • (2006) Metabolism , vol.55 , pp. 711-721
    • Borlak, J.1    Gasparic, A.2    Locher, M.3
  • 45
    • 33744543460 scopus 로고    scopus 로고
    • The role of Gilbert's syndrome and frequent NAT2 slow acetylation polymorphisms in the pharmacokinetics of retigabine
    • Hermann R, Borlak J, Munzel U, et al. The role of Gilbert's syndrome and frequent NAT2 slow acetylation polymorphisms in the pharmacokinetics of retigabine. Pharmacogenomics 2006;6:211-219
    • (2006) Pharmacogenomics , vol.6 , pp. 211-219
    • Hermann, R.1    Borlak, J.2    Munzel, U.3
  • 47
    • 34247252905 scopus 로고    scopus 로고
    • Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures
    • Porter RJ, Partiot A, Sachdeo R, et al. Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures. Neurology 2007;68:1197-1204
    • (2007) Neurology , vol.68 , pp. 1197-1204
    • Porter, R.J.1    Partiot, A.2    Sachdeo, R.3
  • 48
    • 78649984382 scopus 로고    scopus 로고
    • Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy
    • Brodie MJ, Lerche H, Gil-Nagel A, et al. Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy. Neurology 2010;75:1817-1824
    • (2010) Neurology , vol.75 , pp. 1817-1824
    • Brodie, M.J.1    Lerche, H.2    Gil-Nagel, A.3
  • 49
    • 79955592696 scopus 로고    scopus 로고
    • Randomized, double-blind, placebo-controlled trial of ezogabine (retigabine) in partial epilepsy
    • French JA, Abou-Khalil BW, Leroy RF, et al. Randomized, double-blind, placebo-controlled trial of ezogabine (retigabine) in partial epilepsy. Neurology 2011;76:1555-1563
    • (2011) Neurology , vol.76 , pp. 1555-1563
    • French, J.A.1    Abou-Khalil, B.W.2    Leroy, R.F.3
  • 50
    • 84859428190 scopus 로고    scopus 로고
    • The urinary safety profile and secondary renal effects of retigabine (ezogabine): A first-in-class antiepileptic drug that targets KCNQ (Kv7) potassium channels
    • Brickel N, Gandhi P, Vanlandingham K, et al. The urinary safety profile and secondary renal effects of retigabine (ezogabine): A first-in-class antiepileptic drug that targets KCNQ (Kv7) potassium channels. Epilepsia 2012;53:606-612
    • (2012) Epilepsia , Issue.53 , pp. 606-612
    • Brickel, N.1    Gandhi, P.2    Vanlandingham, K.3
  • 51
    • 84872215939 scopus 로고    scopus 로고
    • Advisory committee meeting to discuss antiepileptic drugs (aeds) and suicidality
    • Available from FDA Katz. pdf
    • Katz R. Advisory Committee Meeting to Discuss Antiepileptic Drugs (AEDs) and Suicidality. Memorandum. Available from: Http://www.fda.gov/ohrms/dockets/ ac/08/briefing/2008-4372b1-01-FDAKatz. pdf) 2008
    • (2008) Memorandum
    • Katz, R.1
  • 52
    • 77955291604 scopus 로고    scopus 로고
    • Suicide-related events in patients treated with antiepileptic drugs
    • Arana A, Wentworth CE, Ayuso-Mateos JL, et al. Suicide-related events in patients treated with antiepileptic drugs. N Engl J Med 2010;363:542-551
    • (2010) N. Engl. J. Med. , vol.363 , pp. 542-551
    • Arana, A.1    Wentworth, C.E.2    Ayuso-Mateos, J.L.3
  • 53
    • 0035122602 scopus 로고    scopus 로고
    • Characterization of KCNQ5/Q3 potassium channels expressed in mammalian cells
    • Wickenden AD, Zou A, Wagoner PK, et al. Characterization of KCNQ5/Q3 potassium channels expressed in mammalian cells. Br J Pharmacol 2001;132:381-384
    • (2001) Br. J. Pharmacol. , vol.132 , pp. 381-384
    • Wickenden, A.D.1    Zou, A.2    Wagoner, P.K.3
  • 54
    • 85047690079 scopus 로고    scopus 로고
    • An introduction to antiepileptic drugs
    • Perucca E. An introduction to antiepileptic drugs. Epilepsia 2005;46:31-37
    • (2005) Epilepsia , vol.46 , pp. 31-37
    • Perucca, E.1
  • 55
    • 0030975686 scopus 로고    scopus 로고
    • Lamotrigine substitution study: Evidence for synergism with sodium valproate
    • 105 Study Group
    • Brodie MJ, Yuen AW. Lamotrigine substitution study: Evidence for synergism with sodium valproate? 105 Study Group. Epilepsy Res 1997;26:423-432
    • (1997) Epilepsy Res. , vol.26 , pp. 423-432
    • Brodie, M.J.1    Yuen, A.W.2
  • 56
    • 0032799794 scopus 로고    scopus 로고
    • The efficacy of valproate-lamotrigine comedication in refractory complex partial seizures: Evidence for a pharmacodynamic interaction
    • Pisani F, Oteri G, Russo MF, et al. The efficacy of valproate-lamotrigine comedication in refractory complex partial seizures: Evidence for a pharmacodynamic interaction. Epilepsia 1999;40:1141-1146
    • (1999) Epilepsia , vol.40 , pp. 1141-1146
    • Pisani, F.1    Oteri, G.2    Russo, M.F.3
  • 57
    • 80051547306 scopus 로고    scopus 로고
    • Antiepileptic drug therapy: Does mechanism of action matter
    • Brodie MJ, Covanis A, Gil-Nagel A, et al. Antiepileptic drug therapy: Does mechanism of action matter? Epilepsy Behav 2011;21:331-341
    • (2011) Epilepsy Behav. , vol.21 , pp. 331-341
    • Brodie, M.J.1    Covanis, A.2    Gil-Nagel, A.3
  • 58
    • 5444225675 scopus 로고    scopus 로고
    • Urodynamic effects of the K+ channel (KCNQ) opener retigabine in freely moving, conscious rats
    • Streng T, Christoph T, Andersson KE. Urodynamic effects of the K+ channel (KCNQ) opener retigabine in freely moving, conscious rats. J Urol 2004;72:2054-2058
    • (2004) J. Urol. , vol.72 , pp. 2054-2058
    • Streng, T.1    Christoph, T.2    Andersson, K.E.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.